Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07405398 · ClinicalTrials.gov registry record · NA
A Study to Train a Machine Learning Algorithm for an Evaluation of the Use of Biometric Data Captured at the Wrist for the Identification of Acute Opioid Use Events and the Quantification of Opioid Withdrawal in Opioid Dependent Individuals
A NA study of Treatment for Opioid Use Disorder, sponsored by OpiAID.
- Recruiting
- Registry status
- NA
- Development phase
- 420
- Enrollment target
- 4
- Study locations
NCT07405398: Recruiting NA study of Treatment for Opioid Use Disorder, sponsored by OpiAID.
NCT07405398 is a NA study of Treatment for Opioid Use Disorder that is actively recruiting participants, run by OpiAID. The registered enrollment target is 420 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07405398, a NA study of Treatment for Opioid Use Disorder, is actively recruiting participants, sponsored by OpiAID.
- RECRUITING
- Registry status
- NA
- Development phase
- 420 participants
- Enrollment target
- 4
- Study locations
Study Summary
To train a machine learning model/algorithm for an evaluation of the use of biometric data captured at the wrist for the identification of acute opioid use events and the quantification of opioid withdrawal in opioid dependent individuals.
Primary Outcome
Accurate algorithm-based classification of acute opioid dosing events in patients receiving treatment for opioid use disorder.
Conditions Studied
Interventions
- DEVICE Train and evaluate the accuracy and reliability of the Strength Band Platform in identifying acute opioid dosing events from time-stamped biometric data collected from wrist-worn devices.
Study Locations (4)
Texas
- Community Medical Services - Austin
- Community Medical Services - Austin
- Community Medical Services - Cedar Park
North Carolina
- Coastal Horizon - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What NCT07405398 shows while recruiting
NCT07405398 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Treatment for Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Train and evaluate the accuracy and reliability of the Strength Band Platform in identifying acute opioid dosing events from time-stamped biometric data collected from wrist-worn devices. is the first listed.
NCT07405398 reports a single indexed study location in Texas, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07405398 about?
NCT07405398 is a clinical study titled "A Study to Train a Machine Learning Algorithm for an Evaluation of the Use of Biometric Data Captured at the Wrist for the Identification of Acute Opioid Use Events and the Quantification of Opioid Withdrawal in Opioid Dependent Individuals". To train a machine learning model/algorithm for an evaluation of the use of biometric data captured at the wrist for the identification of acute opioid use events and the quantification of opioid withdrawal in opioid dependent individuals.
What is the current status of trial NCT07405398?
This trial is currently recruiting. It is a NA study. The enrollment target is 420 participants. The study started on 2025-05-01. Estimated completion is 2027-03-31.
What conditions does trial NCT07405398 study?
This clinical trial studies the following conditions: Treatment for Opioid Use Disorder.
What interventions are being tested in trial NCT07405398?
The interventions under investigation include: Train and evaluate the accuracy and reliability of the Strength Band Platform in identifying acute opioid dosing events from time-stamped biometric data collected from wrist-worn devices. (DEVICE).
Who is sponsoring clinical trial NCT07405398?
This trial is sponsored by OpiAID, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07405398 being conducted?
This trial has 4 study locations across North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07405398's enrollment target sits among peer trials
420 239th of 2000 higher than 1,761 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI